Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Current State and Future Prospects of Diagnosis and Management of TP53-Mutated Myeloid Neoplasms.

Pathobiology : journal of immunopathology, molecular and cellular biology - 1 Jan 2024

Venugopal Sangeetha, Loghavi Sanam

Abstract excerpt

TP53-mutated myeloid neoplasms including acute myeloid leukemia (AML) and myelodysplastic neoplasms (MDS) are notoriously treatment resistant with uniformly poor outcomes. TP53 status is an important prognostic indicator and early knowledge of the TP53 mutation/allelic state may assist in appropriate management including clinical trial enrollment for eligible patients. Thus far, no therapy has shown to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Leukemia, Myeloid, Acute
Share to Mutation
Share to Myelodysplastic Syndromes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myeloproliferative Disorders

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 37839402
DOI: 10.1159/000534566

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Current State and Future Prospects of Diagnosis and Management of TP53-Mutated Myeloid Neoplasms.PMID 37839402Read ↗

What have we learned about TP53-mutated acute myeloid leukemia?Semantic proximity Read ↗

TP53 -Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk-Stratification, and Management.Semantic proximity Read ↗

TP53 in AML and MDS: The new (old) kid on the block.Semantic proximity Read ↗

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions.Semantic proximity Read ↗

TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?Semantic proximity Read ↗

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines, Therapies, and Future Considerations.Semantic proximity Read ↗

Molecular and Clinical Insights into TP53-Mutated MDS and AML.Semantic proximity Read ↗

TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches.Semantic proximity Read ↗

Breaking the guardian of the genome: TP53 dysfunction in myeloid neoplasms.Semantic proximity Read ↗

Evaluating targeted therapies in older patients with TP53-mutated AML.Semantic proximity Read ↗

A line in shifting sand: Can we define and target TP53 mutated MDS?Semantic proximity Read ↗

[Advances in the Treatment of Acute Myeloid Leukemia with TP53 Mutations-Review].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.